Californian infectious disease specialist Qpex Biopharma has entered into a multi-product collaboration with Shanghai’s Brii Biosciences.
The firms will work together to develop and commercialize Qpex's portfolio in China of potentially best-in-class therapies to treat a range of multi-drug resistant gram-negative infections.
Brii was launched in 2018 with around $260 million in financial backing. The company aims to accelerate the development and delivery of breakthrough drugs in China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze